Aurora Cannabis arranges $33.76-million bought deal at 0.73¢ 2023-09-28 07:54 ET - News Release
Ms. Michelle Lefler reports
AURORA CANNABIS INC. ANNOUNCES C$34 MILLION BOUGHT DEAL FINANCING INTENDS TO REPAY REMAINING CONVERTIBLE DEBT BALANCE
Aurora Cannabis Inc. has entered into an agreement pursuant to which Canaccord Genuity Corp. has agreed to buy, on a bought deal basis, 46.25 million common shares of the company at a price of 73 cents per offered security for aggregate gross proceeds to Aurora of approximately $33,762,500.
Aurora has also granted Canaccord Genuity an option to purchase up to 6,937,500 additional common shares of the company on the same terms as the offering. If the overallotment option is exercised in full, the aggregate gross proceeds of the offering will be approximately $38,826,875.
The company plans to use the net proceeds of the offering to repay the remainder of its outstanding convertible senior notes at or prior to maturity, representing principal outstanding of approximately $25-million (U.S.), with the remainder, if any, to be used for strategic purposes, including potential acquisitions.
The closing of the offering is expected to take place on or about Oct. 3, 2023, and will be subject to customary conditions, including the approval of the Toronto Stock Exchange.
A prospectus supplement to the company's short form base shelf prospectus dated April 27, 2023, will be filed with the securities commissions or securities regulatory authorities in each province of Canada, except Quebec. Copies of the prospectus supplement, following the filing thereof, and the base shelf prospectus may be obtained on SEDAR+ and from Canaccord Genuity, 40 Temperance St., suite 2100, Toronto, Ont., M5H 0B4. The prospectus supplement and the base shelf prospectus contain important detailed information about the company and the proposed offering. Prospective investors should read the prospectus supplement, the base shelf prospectus and the other documents the company has filed on SEDAR+ before making an investment decision.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched.